Skip to main content
    P

    Plus Therapeutics Inc (PSTV)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.69
    -0.05 (-2.87%)

    Market Cap: $26.64M

    Last updated: Oct 14, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    66%(25/38)
    Avg Surprise
    +8.81%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.86
    Range$-0.92 - $-0.80
    3 analysts
    EPS RevisionsNo revisions (7d)
    1
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.81-5.8%
    60d ago$0.00n/a
    30d ago$-0.85-1.2%
    7d ago$-0.860.0%
    Current$-0.86
    Revenue Consensus
    $1M
    Range$1M - $2M
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.31
    Range$-2.17 - $-0.78
    4 analysts
    Revenue Consensus
    $3M
    Range$450750 - $7M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.31---
    Sep 26EST
    		-$-0.86---
    Jun 26
    Reported Aug 13
    		$N/A$-0.96N/ABeat-
    Mar 26
    Reported May 15
    		$-1.05$-0.87-20.69%Miss+92.6%
    Dec 25
    Reported Mar 12
    		$-0.04N/A+95.51%Beat+91.6%
    Sep 25
    Reported Oct 30
    		$-1.00$-0.87-14.94%Miss+89.2%
    Jun 25
    Reported Aug 14
    		$-0.16N/A+95.08%Beat+98.6%
    Mar 25
    Reported May 30
    		$-14.17$-7.33-93.32%Miss+24.4%
    Dec 24
    Reported Mar 27
    		$-0.49$-0.50+1.35%Beat+41.7%
    Sep 24
    Reported Nov 14
    		$-9.25$-14.06+34.21%Beat+63.0%
    Jun 24
    Reported Aug 14
    		$-11.25$-13.25+15.09%Beat+23.7%
    Mar 24
    Reported May 15
    		$-18.75$-27.25+31.19%Beat+64.3%
    Dec 23
    Reported Mar 5
    		$-0.84$-1.07+21.50%Beat-281.8%
    Sep 23
    Reported Oct 31
    		$-25.00$-29.42+15.02%Beat+64.9%
    Jun 23
    Reported Aug 14
    		$-14.75N/A+70.94%Beat+83.6%
    Mar 23
    Reported Apr 20
    		$-52.50$-55.00+4.55%Beat+26.3%
    Dec 22
    Reported Feb 23
    		$-0.22$-0.12-83.33%Miss+18.5%
    Sep 22
    Reported Oct 20
    		$-71.25$-80.00+10.94%Beat+32.0%
    Jun 22
    Reported Jul 21
    		$-90.00$-71.25-26.32%Miss+4.0%
    Mar 22
    Reported Apr 21
    		$-71.25$-71.25+0.00%Beat+42.4%
    Dec 21
    Reported Feb 24
    		$-0.27$-0.27+0.00%Beat+59.7%
    Sep 21
    Reported Oct 21
    		$-104.77$-91.25-14.82%Miss+28.4%
    Jun 21
    Reported Jul 22
    		$-93.75$-93.75+0.00%Beat-35957.7%
    Mar 21
    Reported Apr 22
    		$-123.75$-146.25+15.38%Beat+53.5%
    Dec 20
    Reported Feb 22
    		$-0.67$-0.39-71.79%Miss-391.3%
    Sep 20
    Reported Oct 22
    		$-146.25$-206.25+29.09%Beat-1200.0%
    Jun 20
    Reported Aug 10
    		$-0.26N/A+65.33%Beat+100.0%
    Mar 20
    Reported May 14
    		$-266.14$-281.25+5.37%Beat+92.1%
    Dec 19
    Reported Mar 30
    		$0.23N/A+134.85%Beat+102.9%
    Sep 19
    Reported Nov 14
    		$-11.25N/A+99.49%Beat+99.9%
    Jun 19
    Reported Aug 15
    		$-1920.00$-3750.00+48.80%Beat+82.6%
    Mar 19
    Reported May 14
    		$-3375.00$-3656.25+7.69%Beat+74.3%
    Dec 18
    Reported Mar 29
    		$-8.05$-14.67+45.13%Beat+83.9%
    Sep 18
    Reported Nov 14
    		$-10312.49$-4500.00-129.17%Miss+60.7%
    Jun 18
    Reported Aug 14
    		$-11062.49$-8925.00-23.95%Miss+68.9%
    Mar 18
    Reported May 10
    		$-13124.99$-10000.00-31.25%Miss+73.1%
    Dec 17
    Reported Mar 8
    		$-50.00$-42.50-17.65%Miss+58.3%
    Sep 17
    Reported Nov 9
    		$-26249.99$-29374.99+10.64%Beat-
    Jun 17
    Reported Aug 10
    		$-35624.98$-33749.98-5.56%Miss-
    Mar 17
    Reported May 11
    		$-48749.98$-57187.47+14.75%Beat-
    Dec 16
    Reported Mar 23
    		$-120.00$-115.00-4.35%Miss-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCF-0.50xFCF Yield-201.98%
    Profitability
    Profit Margin-230.20%Operating Margin-693.00%
    ROE-522.00%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio1.37xQuick Ratio1.37x
    Trading Statistics
    Beta1.42Avg Volume175.14K
    52-Week High$23.4352-Week Low$2.90

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.71
    SMA 20$1.83
    SMA 50$2.56
    SMA 200$5.31
    EMA 10$1.77
    EMA 20$1.91
    EMA 50$2.50
    EMA 200$5.48

    MACD

    Line: -0.23Signal: -0.28Hist: 0.05

    ADX

    ADX: 23.4+DI: 20.4-DI: 23.6

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down72.0
    PSAR$2.07

    Bollinger Bands

    Upper Band$2.15
    Lower Band$1.52
    %B Position3425%(Upper)
    Band Width0.27

    RSI (14-Day)

    Neutral
    35.6

    Momentum Oscillators

    Stoch %K32.9
    Stoch %D40.3
    Williams %R-74.2
    ROC (10d)-9.6%
    Momentum-0.18
    CCI (20d)-88.1
    MFI (14d)21.1

    Volatility Measures

    ATR (14d)$0.20(11.9%)
    StdDev (20d)0.16
    Hist Vol87.0%(High)

    Volume Flow

    VWAP$1.67
    OBV1.6B
    AD Line1202.5B
    CMF (20d)-0.300

    Volume Metrics

    Avg Vol (20d)184.6K
    Vol Ratio0.4x(Low)
    VWMA (20d)$1.81

    Pivot Points

    R3$1.99
    R2$1.90
    R1$1.82
    Pivot Point$1.73
    S1$1.65
    S2$1.56
    S3$1.48

    Advanced Oscillators

    TSI-34.32
    Ultimate Osc51.3
    KST-310.99

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$411,000$1.03M$1.37M$1.40M$1.39M$1.06M$1.41M$1.46M$1.28M$1.68M$1.31M$1.24M
    Cost of Revenue$0$0$92,000$0$0$0$232,000$0$0$0$182,000$0
    Gross Profit$411,000$1.03M$1.37M$1.40M$1.39M$1.06M$1.41M$1.46M$1.28M$1.68M$1.31M$1.24M
    Operating Expenses$9.47M$8.15M$7.11M$5.88M$2.93M$4.59M$5.31M$5.25M$4.98M$4.98M$5.17M$4.49M
    R&D$4.26M$2.87M$2.94M$2.44M$1.25M$1.76M$2.19M$2.86M$2.77M$2.76M$2.79M$2.49M
    SG&A$5.20M$5.28M$4.17M$3.44M$1.68M$2.84M$3.13M$2.40M$2.20M$2.21M$2.38M$2.00M
    Operating Income$-9,057,000$-7,119,000$-5,742,000$-4,482,000$-1,538,000$-3,536,000$-3,900,000$-3,799,000$-3,697,000$-3,299,000$-3,858,000$-3,251,000
    Interest Income$56,000$190,000$29,000$59,000$27,000$1,000$54,000$80,000$67,000$72,000$110,000$119,000
    Interest Expense$5,000$17,000$0$0$0$548,000$57,000$61,000$27,000$34,000$62,000$87,000
    Income Before Tax$-9,006,000$-6,946,000$-5,713,000$-4,423,000$5.15M$-17,401,000$-3,903,000$-2,874,000$-2,940,000$-3,261,000$-3,810,000$-3,219,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-9,006,000$-6,946,000$-5,713,000$-4,423,000$5.15M$-17,401,000$-3,903,000$-2,874,000$-2,940,000$-3,261,000$-3,810,000$-3,219,000
    EBITDA$-8,900,000$-7,031,000$-5,587,000$-4,402,000$5.14M$-16,673,000$-3,613,000$-2,741,000$-2,830,000$-3,127,000$-3,763,000$-3,022,000
    EBIT$-9,057,000$-7,119,000$-5,742,000$-4,482,000$5.12M$-16,854,000$-3,900,000$-2,893,000$-2,980,000$-3,299,000$-3,858,000$-3,251,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PSTV

    News

    CNSY - PSTV: 15 Million Financing And Prefunded Warrants Will Drive Clinical Progress

    Plus Therapeutics (PSTV) has secured $15 million in financing and prefunded warrants, which analysts believe will accelerate clinical progress. While some analysts are bullish on the long-term potential...

    Simply Wall Street•8/6/26•Somewhat-Bullish

    Plus Therapeutics amends bylaws to reflect corporate name change to Cerenome

    Plus Therapeutics has amended its bylaws to reflect a corporate name change to Cerenome, effective August 3, 2026. The company's Nasdaq trading symbol also switched to CNSY on the same date...

    Bitget•8/5/26•Neutral

    Plus Therapeutics presents REYOBIQ data at neurosurgery meeting

    Plus Therapeutics (PSTV) presented encouraging clinical data for its radiopharmaceutical REYOBIQ at the 2026 American Association of Neurological Surgeons Annual Scientific Meeting. The data from the Phase 1 ReSPECT-LM...

    Investing.com•8/5/26•Bullish

    Discontinued operations of PLUS THERAPEUTICS, Inc. – NASDAQ:CNSY

    This article briefly reports on the discontinued operations of PLUS THERAPEUTICS, Inc. (NASDAQ: CNSY). The content is minimal...

    TradingView•8/3/26•Bearish

    Cash flow from financing activities of PLUS THERAPEUTICS, Inc. – BOATS:CNSY

    This article focuses on the cash flow from financing activities for PLUS THERAPEUTICS, Inc. (CNSY) as displayed on TradingView. It provides a financial overview of the company...

    TradingView•8/3/26•Neutral

    PSTV Valuation and Fair Value

    Forward P/E
    1.0x
    P/FCF
    -0.5x
    PEG
    2.5x
    P/B
    2.1x
    See GNG's fair value

    PSTV Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -693.0%
    Net margin
    -230.2%
    ROE
    -522.0%
    FCF margin
    -560.3%
    FCF yield
    -202.0%

    PSTV Competitors

    CompanyTicker
    OneMedNet Corp.ONMD
    India Globalization Capital IncIGC
    Transcode Therapeutics IncRNAZ
    SRx Health Solutions Inc.SRXH
    MIRA Pharmaceuticals, Inc. Common StockMIRA
    PetMed Express IncPETS
    Evoke Pharma IncEVOK
    Seres Therapeutics IncMCRB

    Sector: Healthcare

    PSTV Analyst Ratings

    Consensus
    Buy
    Analysts
    4
    Strong Buy
    1
    Buy
    3
    Hold
    0
    Sell
    0
    Strong Sell
    0

    PSTV Bull Case vs Bear Case

    Bear case

    • PSTV has a -230.2% net profit margin.
    • PSTV's quarterly revenue changed -2.9% year over year.

    PSTV Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    14.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.86
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 2 down

    Frequently Asked Questions About PSTV

    Does PSTV pay dividends?

    Plus Therapeutics Inc (PSTV) does not currently pay a regular dividend.

    What is PSTV's market cap?

    Plus Therapeutics Inc (PSTV) has a market capitalization of $26.64M with a current stock price of $1.69.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In